Bacil Pharma Quarterly Results for Trading Insights
In 2026, Bacil Pharma (BACPHAR) reported revenue ₹1 Cr and net profit ₹1 Cr. Compare with BACPHAR stock valuation models to assess whether the stock is under or overvalued.
BACPHAR Quarterly Results — Revenue, Profit & EPS Highlights
Bacil Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Bacil Pharma stock price NSE.
- Revenue of ₹1 Cr in March 2025 (+0.0% vs March 2025)
- Earnings Per Share of ₹0.64 in March 2025 (+0.0% vs March 2025)
Bacil Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BACPHAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1 | 1 | 0 | 0 | 0 | - | - |
| Net Profit (₹ Cr) | 1 | 0 | 0 | 0 | -4 | - | - |
| EBITDA (₹ Cr) | 1 | 0 | 0 | 0 | -4 | - | - |
| EPS (₹) | 0.60 | 0.64 | -0.10 | -0.17 | -6.55 | - | - |
| Operating Margin (%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | - |
BACPHAR Share Price Trend — 1-Year Movement Across Quarterly Results
Bacil Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore BACPHAR price trends to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BACPHAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bacil Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹443,373.10 Cr | 1863.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 143.3 |
|
Divis Laboratories
Sept 2025 |
₹178,235.60 Cr | 6921.5 | 2,860 | 689 | +7.1% | - | 24.1% | 266.5 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹145,389.39 Cr | 4403.9 | 3,219 | 591 | +11.3% | - | 18.4% | 251.1 |
|
Cipla
Mar 2026 |
₹107,240.96 Cr | 1436.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹105,607.38 Cr | 1303.6 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 491.9 |
All amounts in ₹ Crores